Warning: There are an increasing number of fraudulent websites that impersonate ECCMID. We would like to alert all our members and delegates to possible scams and we strongly advise you to use only the official ECCMID online registration and accommodation services for your bookings.

Abstract Categories

Abstracts can be submitted from 2 October to 28 November 2019


1. Viral infection & disease

a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, treatment & susceptibility/resistance)

b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance)

c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, treatment, excl vaccination)

d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)

e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (all aspects)

f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

g. Viral epidemiology – general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)

h. Antiviral drugs, treatment, susceptibility/resistance (other than respiratory viruses, herpesviruses, hepatitis & HIV)

i. Other


2. Bacterial infection & disease

a. Tuberculosis and other mycobacterial infections (incl antimycobacterial drugs, treatment & susceptibility/resistance, diagnostics & epidemiology)

b. Severe sepsis, bacteraemia & endocarditis (incl host bio-markers)

c. Community-acquired respiratory infections

d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections

e. Skin, soft tissue, bone & joint (excl prostheses) & central nervous system infections

f. Zoonotic bacterial diseases (incl foodborne and waterborne pathogens and One Health aspects)

g. Other intracellular or rare bacteria

h. Other


3. Bacterial susceptibility & resistance

a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives

b. Resistance surveillance & epidemiology: Gram-negatives

c. Susceptibility testing methods (incl assay validation and comparative studies, excl TB)

d. Resistance mechanisms (excl TB)

e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)

f. Other


4. Diagnostic bacteriology & general microbiology

a. Diagnostic bacteriology – culture based and general microbiology

b. Lab management, automation and QC

c. MALTI-TOF and other proteomic methods

d. Molecular diagnostics (incl POCT and syndromic testing)

e. Molecular and genomic typing and surveillance

f. Whole genome sequencing (diagnostic)

g. Microbiome studies (incl One Health aspects)

h. Clinical metagenomics

i. Bioinformatics tools & pipelines

j. Other


5. New Antibacterial Agents, PK/PD & Stewardship

a. Mechanisms of action, new compounds, preclinical data & pharmacology of antibacterial agents

b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring

c. New or repurposed antibacterial agents: clinical trials

d. Pharmacoepidemiology (incl economics and cost-effectiveness), improved prescribing and antibiotic stewardship (incl decision-support / prediction tools, behavioural aspects)

e. Other


6. Fungal infection & disease

a. Fungal disease epidemiology 

b. Diagnostic mycology (incl molecular)

c. Antifungal drugs & treatment (incl clinical trials)

d. Antifungal resistance & susceptibility testing (incl surveillance)

e. Other


7. Parasitic diseases & International health

a. Diagnostic parasitology

b. Antiparasitic susceptibility & resistance

c. Antiparasitic drugs & treatment

d. Parasitic disease epidemiology

e. Travel medicine & migrant health

f. Food & water safety and environmental health

g. International & public health

h. Other


8. Healthcare-associated & Nosocomial Infections, Infection Control

a. Intravascular catheter-related infections

b. Other foreign-body and implant infections

c. Surgical site infections

d. Healthcare-associated pneumonia

e. Nosocomial infection surveillance & screening methods

f. Epidemiology and transmission (incl observational studies)

g. Infection control interventional trials (incl. microbiota transplantation)

h. Disinfection & biocides

i. Other


9. Experimental Microbiology, Microbial Pathogenesis & Biofilm

a. Microbial pathogenesis & virulence

b. Host-pathogen interaction

c. Preclinical biofilm studies

d. Experimental and cellular microbiology

e. Other


10. Immunology & Vaccinology

a. Host genetics: infection susceptibility & immunodeficiency

b. Clinical epidemiology of infections in immunocompromised hosts

c. General vaccinology (incl. policy, social aspects)

d. Antiviral vaccines

e. Antibacterial vaccines

f. Immune response to infection (excl sepsis biomarkers)

g. Other


11. Other

a. Education and career

b. Publishing, ethics, other academic and professional affairs

c. Other


Late breakers

21. New drugs

22. Clinical trials

23. Outbreaks and public health emergencies

24. Other